Genentech Inc And Others v. Drugs Controller General Of India And Others

In the high-stakes world of pharmaceutical intellectual property, confidential clinical data is often treated like crown jewels — locked away, guarded fiercely, and shown to no one. But what happens when that very secrecy becomes a roadblock to justice? The Genentech Inc. case before the Indian courts in March 2020 serves as a powerful reminder that even the most sensitive data cannot be used as a shield to deny a party its fundamental right to defend itself.

Genentech Inc. and others found themselves in a commercial intellectual property dispute involving a biosimilar drug — a complex area where the line between innovation and imitation is razor-thin. At the heart of the conflict was a trove of confidential clinical and pre-clinical test data, the kind of information that forms the scientific backbone of any drug approval. The plaintiffs had their own internal expert, Dr. Samir Sagitrao, who was prepared to inspect this sensitive material. Defendant No. 3, however, sought to restrict Dr. Sagitrao's participation in that inspection, raising concerns about the exposure of proprietary and confidential information.

Defendant No. 3's argument was rooted in the protection of sensitive clinical and pre-clinical data — information that, if leaked or mishandled, could compromise years of research and competitive advantage. The push was to keep the plaintiffs' expert at arm's length from this material. On the other side stood the principle of fair legal contest: the defendants in the broader suit needed access to the very documents and data being claimed by the opposing party to mount a meaningful defense. The legal friction was clear — how do you reconcile the legitimate need for confidentiality with the equally legitimate right to a fair hearing?

The court came down firmly on the side of fairness. It dismissed the application by Defendant No. 3 seeking to restrict Dr. Samir Sagitrao's participation in the inspection of the confidential data. The court's reasoning was straightforward and powerful: defendants in a commercial suit cannot be expected to contest the case effectively if they are deprived of access to the documents and information claimed by the opposing party — even when that information is confidential. The right to defend oneself, the court affirmed, cannot be sacrificed at the altar of data secrecy.

For founders, startup leaders, and IP professionals, the lesson is sharp and actionable: confidentiality is not a trump card. In commercial IP disputes, you must be prepared to facilitate controlled access to sensitive data so that the opposing party can fairly defend its position. Build robust confidentiality protocols — secure inspection rooms, signed non-disclosure agreements, restricted expert access — rather than trying to block inspection altogether. Trying to hide the evidence entirely can backfire, leaving the court to rule against you. In IP litigation, transparency within protective boundaries is not just good ethics — it's good strategy.